Healthcare Services Group Stock Price and Value Analysis

Healthcare Services Group (NasdaqGS:HCSG) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Healthcare Services Group to reach your target.

Target type

HCSG Free Cash Flow Trend

Free Cash Flow trendline for HCSG
Free Cash Flow trendline for Healthcare Services Group
CSV

Based on historical returns, we believe that Healthcare Services Group can grow its free cash at a rate of about 9%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This company is solid.
  • This stock is on sale.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the HCSG Numbers

HCSG Price
(Healthcare Services Group stock price per share)
$24.72
[?] HCSG Fair Price
(based on intrinsic value)
$29.75
[?] HCSG Safety Price (based on a variable margin of safety) $19.34
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 17% lower than other Healthcare stocks
[?] PE Ratio versus Industry 24% higher than other Medical Care Facilities stocks
[?] Cash Yield 3.95%
[?] Free Cash Flow Jitter 92%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,483,447 shares shorted. With 66,672,048 shares available for purchase and an average trading volume over the past 10 trading days of 490,510, it would take at least 5.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 731012 15.1
2009 731012 36.4
2010 731012 35.1
2011 731012 29.6
2012 731012 57
2013 731012 28.3
2014 731012 53.2
2015 731012 58.6
2016 731012 36.7
2017 731012 2.6
2018 731012 74.7
2019 731012 88.6
2020 731012 212
2021 731012 32.2
2022 731012 -13.1
2023 731012 38.5
2024 731012 25.4
2025 731012 139

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 18 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $1,027 million against net income of $933 million, or 1.10 times.

In 2025, operating cash flow was 2.45 times net income, compared with 1.01 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $5.8 million, 4.0% of operating cash flow of $145 million, which leaves an estimated $139 million after capex. Across the 17 years with reported capex, it averaged 7.7% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 26.6 16.7 1.6 0.63
2009 30.3 38.3 2.2 1.26
2010 34.4 37.7 4.2 1.10
2011 38.2 32.9 5.5 0.86
2012 44.2 60.4 3.5 1.37
2013 47.1 32.2 3.8 0.68
2014 21.9 57.7 5.8 2.64
2015 58 63.4 5 1.09
2016 77.4 41.4 5.4 0.53
2017 88.2 7.6 5.4 0.09
2018 83.5 80 4.9 0.96
2019 64.6 93.6 4.4 1.45
2020 98.7 217 4.3 2.20
2021 48.5 37.1 5.7 0.76
2022 34.2 -8.2 5.2 -0.24
2023 38.4 43.5 5.4 1.13
2024 39.5 30.8 6.3 0.78
2025 59.1 145 5.8 2.45

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $637 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 7 of those years with dividend payment facts, dividends paid totaled $411 million, 94.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 3 of those 7 years.

In 4 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $99.4 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $61.6 million, 44.2% of estimated free cash flow of $139 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 36.7 53.3 n/a 53.3 145.3%
2017 2.6 55.2 n/a 55.2 2165.4%
2018 74.7 57.2 n/a 57.2 76.6%
2019 88.6 59 n/a 59 66.6%
2020 212 60.7 n/a 60.7 28.6%
2021 32.2 62.2 21.5 83.8 260.4%
2022 -13.1 63.4 n/a 63.4 n/a
2023 38.5 n/a 11.3 11.3 29.3%
2024 25.4 n/a 5 5 19.8%
2025 139 n/a 61.6 61.6 44.2%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,563 million in 2016 and $1,837 million in 2025, a compound annual growth rate of 1.8% over 9 years.

Revenue rose 7.1% from 2024 to 2025.

Our estimated free cash flow was $139 million in 2025, 7.6% of revenue. In 2016 the estimated margin was 2.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 1,563 36.7 2.3%
2017 1,861 2.6 0.1%
2018 2,003 74.7 3.7%
2019 1,841 88.6 4.8%
2020 1,760 212 12.1%
2021 1,642 32.2 2.0%
2022 1,690 -13.1 -0.8%
2023 1,671 38.5 2.3%
2024 1,716 25.4 1.5%
2025 1,837 139 7.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $125 million against total liabilities of $284 million, or 44.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 35.8% of total assets in 2025, compared with 21.5% in 2009, an increase of 14.3 percentage points.

Stockholders equity was $510 million in 2025, compared with $209 million in 2009, a rise of 144.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 27.9% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 266 31.3 57.1 209
2010 278 39.7 64.9 213
2011 290 38.6 72 218
2012 331 68.9 102 230
2013 425 64.2 140 285
2014 470 75.3 194 276
2015 481 33.2 184 296
2016 528 23.9 190 339
2017 676 9.6 276 400
2018 693 26 252 441
2019 723 27.3 262 460
2020 785 139 315 470
2021 780 70.8 332 445
2022 721 26.3 303 418
2023 791 54.3 334 457
2024 803 56.8 303 500
2025 794 125 284 510

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $24.72, our model's value equals that price if free cash flow grows an average of 6.0 percent a year over the 10 projection years. Our model assumes 9.5 percent a year for this stock, so the price implies growth of 6.0 percent, which is below the 9.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $66.1 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $19.78 1.4%
Current price $24.72 6.0%
20 percent above the current price $29.66 9.4%
Our model (stored fair price) $29.75 9.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Positive free cash flow appears in 17 of the 18 fiscal years we hold for Healthcare Services Group from its current SEC filer.

Healthcare Services Group at $24.72 lies between its safe value ($19.34) and its fair value ($29.75).

Free cash flow from the first three years of data averaged $28.9 million, and from the last three $67.7 million: a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 92%.

Dividends are not in our data for Healthcare Services Group.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 17% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 24% above the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to Healthcare Services Group, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below
U.S. Physical Therapy (USPH) 1,432 - 1.9% 3.0% 1% below
Progyny (PGNY) 2,630 32.8 - - 409% above
Surgery Partners (SGRY) 3,505 - - - 105% above
DaVita (DVA) 10,129 12.2 - 15.2% 57% below
Universal Health Services (UHS) 10,345 7.5 0.5% 14.1% 71% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 731012.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: HCSG annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HCSG

Does Healthcare Services Group have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HCSG

This example shows how we apply the Trendshare checklist to HCSG: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 24.72
    • Market cap: $1.7B
    • EPS: 1.48
  2. Step 2 — Valuation checks

    • P/E: 16.703
    • FCF yield: 4.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.